In 2006, when the US National Oceanic and Atmospheric Administration, or NOAA, released the first-ever Arctic Report Card, scientists already knew the top of the world was in trouble. It’s now much ...

The Arctic last season was the hottest it has been in the past 125 years. The extent of sea ice during its usual maximum in March was the lowest in 47 years of satellite recordkeeping. The North ...

Senior Scientist, National Snow and Ice Data Center (NSIDC), Cooperative Institute for Research in Environmental Sciences (CIRES), University of Colorado Boulder Matthew L. Druckenmiller receives ...

Hundreds of Arctic rivers and streams are turning bright red-orange, not from chemical pollution, but from naturally occurring iron spilling from long-frozen ground as temperatures warm. The "rusting ...

The Arctic has experienced its hottest year since records began, a US science agency announced Tuesday, as climate change triggers cascading impacts from melting glaciers and sea ice to greening ...

The Arctic is a dramatically different place than it was 20 years ago, when scientists first began giving it an annual checkup—and its current state is dire. The first Arctic Report Card was released ...

We recently published 10 Stocks Delivering Explosive 18-190% Gains. Terns Pharmaceuticals, Inc. (NASDAQ:TERN) is one of the last week’s heavy gainers. Terns Pharmaceuticals soared by 53 percent in ...

Terns Pharmaceuticals, Inc. stock has surged 770% YTD, driven by strong TERN-701 data in chronic myeloid leukemia, or CML, the latest outstanding data set shared yesterday. TERN-701 demonstrated ...

We recently published 10 Stocks Standing Tall Amid Market Fall; 6 Hit Record Highs. Terns Pharmaceuticals, Inc. (NASDAQ:TERN) is one of the best performers on Monday. Terns soared to a new all-time ...

Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall Street, and biotechnology. He is also a co-host of the weekly biotech podcast ...

The average one-year price target for Terns Pharmaceuticals (NasdaqGS:TERN) has been revised to $31.05 / share. This is an increase of 16.10% from the prior estimate of $26.75 dated November 14, 2025.

Tern, the technology platform designed for travel agents, is launching a new expansion of its platform with new booking technology through Project Expedition and future travel insurance partnerships.